With the approval of the National Medical Products Administration, Shanghai WD Pharma is sponsoring a Phase II clinical trial of WD-1603 for the treatment of early-onset idiopathic Parkinson's disease using "Next-Generation Carbidopa/Levodopa Controlled-Release Tablets." The trial is being conducted by Huashan Hospital affiliated with Fudan University, the Second Hospital affiliated with Soochow University, Xiangya Hospital of Central South University, and the First Hospital affiliated with Sun Yat-sen University.